2021-09-30-accounts

Orchid Cancer Appeal Annual report and fi nancial statements 2020–2021

Orchid Cancer Appeal, known as Orchid, is a small, in fl uential charity solely dedicated to improving the lives of men of all ages who are at risk of, or affected by male cancer. For over 25 years we have been working to save men’s lives from prostate, testicular and penile cancer through a range of support services, education and awareness campaigns, and a world-class research programme.

4 Orchid Cancer Appeal

Board of Trustees

Mr CS Osborne Chair Mr W Cohen Treasurer Mr D Badenoch Mr PG Bracher Mr S Harris Mr M Kibblewhite Professor RTD Oliver Mr P Norman Mr S Seymour (resigned 1 January 2022) Mr N Watkin (resigned 7 December 2021)

Chief Executive

Mr A Orhan (appointed interim Chief Executive 24 Apr 2020 and as Chief Executive 8 Jan 2021)

Independent Examiner

Moore Kingston Smith LLP 6th Floor, 9 Appold Street, London EC2A 2AP

Registered Of fi ce

60 Gray’s Inn Road, London WC1X 8AQ

Tel [phone] www.orchid-cancer.co.uk

Registered in England with the Charity Commission No.1080540

Company Limited by Guarantee Registered in England No. 3963360

Accountants

JS2 Limited 1 Crown Square, Woking, Surrey GU21 6HR

Legal advisors

Farrer & Co 66 Lincoln’s Inn Fields, London WC2A 3LH

Bankers

HSBC Plc 20 Electric Parade, George Lane, South Woodford, London E18 2LX

Annual report and fi nancial statements 2020-2021 5

Orchid Cancer Appeal Annual report and fi nancial statements 2020–2021

Welcome from our Chair 6 CEO’s letter 7 The year in review 10 The year in numbers 12 Fundraising 14 Our impact 18 Prostate cancer 20 Testicular cancer 22 Penile cancer 24 Research 28 The year ahead 32 Governance 36 Objects, operating context and activities 36 Structure, Governance and Management 37 Financial review 40 Formal statements 40 Independent Examiner’s information 41 Independent Examiner’s Report 42 Statement of fi nancial activities 43 Balance sheet 44 Statement of cash ows 45 fl Notes to the fi nancial statements 46

6 Orchid Cancer Appeal

Welcome from our Chair

The Trustees came together last year to look at new avenues of work while maintaining our focus, and I am pleased to report that our efforts have continued with tremendous success.

The Trustees advertised for a permanent CEO, and I am delighted to report that Ali Orhan who had been our Interim Chief Executive was appointed to the position.

I am very proud that our work in 2020 - 2021 was delivered with the same level of adaptability and resourcefulness that was shown in the previous year in response to the ongoing COVID-19 pandemic. We continued to work on raising awareness of prostate, testicular and penile cancers and supporting men with a diagnosis.

In September 2021 it was an honour to attend the renaming of the Orchid Research Tissue Bank which is now the Robert Lane Tissue Bank, renamed as tribute to the wonderful contribution Orchid’s late Chair of Trustees, Robert Lane, made to the charity. The need to invest in research remains clear, so Orchid continued to support world-class research with our biggest grant being made to fund the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells project.

Commencing with the recruitment of the staff team, Orchid has started on delivery of a substantial three-year programme of work entitled Overcoming the Barriers to Engaging with Prostate Cancer , funded by the National Lottery Community Fund. We thank the National Lottery for affording Orchid the opportunity to reach men at high risk and in some of the most deprived areas of the country.

In 2021 we said sad farewells to two long term and loyal supporters of Orchid, and I would like to pay tribute to them.

Roy Dickins passed away in August 2021 after a long illness. Together with his wife June, Roy was an avid Orchid fundraiser for many years. He was as well known for his quirky fund raising ideas as he was for his annual Christmas jumper. RIP Roy.

Roger Hunt MBE died in September 2021. Roger was a member of the 1966 World Cup winning England football team, and was a valued Ambassador for Orchid. RIP Roger.

I would like to thank the Orchid Trustees, CEO, and staff for continuing to deliver our services through these challenging times. Together I hope that we can continue to make Orchid successful and make further advancement in fi ghting the battle against cancer for men.

Colin Osborne MBE

Annual report and fi nancial statements 2020-2021 7

CEO’s letter

Educating people about male cancers and the bene fi ts of an early diagnosis was a priority throughout 2020–2021, as Orchid was concerned that signi fi cant numbers of men were not presenting with cancer symptoms. With COVID-19 restrictions in place for much of the year, Orchid had to respond by adapting our support and practice once again. For this reason, technology and social media played a greater role in order to not only relay health messages, but also to deliver support through virtual sessions and online help, augmenting our face to face work.

With the team in place to deliver the National Lottery Community Fund programme Overcoming the Barriers to Engaging with Prostate Cancer, this work commenced in May. In September, our annual Male Cancer Awareness Week was once again delivered mostly digitally and had a particular focus on penile cancer for the fi rst time. Two highlights from the Week were the launch of a new animated fi lm called My Penile Cancer Journey, and the release of a moving video featuring photographs of male loved ones.

The Week led to the fi rst International Penile Cancer Awareness Day and a global virtual conference on penile cancer which was developed in partnership with the Global Society of Rare Genitourinary Tumours and the Australian charity, Check Your Tackle.

In line with COVID-19 restrictions, our Community Engagement Team continued to take information directly to households in targeted areas and we provided opportunities for people to attend online sessions with an Orchid Nurse. As the external environment opened up, we were also able to deliver Male Cancer Information Roadshows in Bury, Croydon, Liverpool and Preston.

I believe that this blend of working virtually, using technology and delivering in person gives Orchid the opportunity to increase its reach and provide more information to a more diverse audience, and I am grateful for the dedication of Orchid’s staff and volunteers, and the support of Trustees.

Ali Orhan, CEO

‘You go through life trying not to think about things like prostate cancer. Then Orchid comes

----- Start of picture text -----
Annual report and fi nancial statements 2020-2021 9
----- End of picture text -----

10 Orchid Cancer Appeal

Opposite: A scene from the animated short fi lm My Penile Cancer Journey, launched on social media during Male Cancer Awareness Week, September 2021

The year in review

2019-2020 had ended on a high note with the successful predominantly digital delivery of Orchid’s Male Cancer Awareness Week. This was just one example that had showcased Orchid’s ability to adapt its way of working to meet the challenges presented by COVID-19 and the changing external environment.

played a greater role in the relaying of health messages with posts directing people to our website for information or to download or request resources, as well as to our Your Privates testicular cancer microsite. We were not surprised therefore to see increased traf c to both sites.

Work throughout 2020-2021 was delivered with that same level of adaptability in response to ongoing low male cancer awareness, the demand for information and support for those living with a male cancer diagnosis, and the need to invest in world-class research into the causes, potential prevention, and treatment of male cancers.

Orchid’s Nurse-led services continued to be reviewed on an ongoing basis to ensure we could safely meet the needs of those living with or at risk of prostate, testicular or penile cancer..

Educating people about male cancer and the bene fi ts of an early diagnosis if needed was a priority throughout the year, especially considering our concern that signi fi cant numbers of people were not presenting with cancer symptoms. Social media

Reaching those at risk was a priority, and many of our awareness activities targeted individuals in areas of deprivation where people are often less likely to engage with traditional health services. In line with COVID-19 restrictions, our Community Engagement Team continued to take information directly to households in targeted areas, we promoted our services widely including via healthcare professionals, and provided opportunities for people to attend online sessions with an Orchid Nurse. Most male cancer talks were delivered virtually.

Delivery of a new project, Overcoming the Barriers to Engaging with Prostate Cancer, which is funded by The National Lottery Community Fund, began in May. Volunteer Community Champions will work in 10 locations across England to cascade prostate cancer messages in their local areas. September saw Orchid return to the heart of local communities to deliver

Annual report and fi nancial statements 2020-2021 11

Male Cancer Information Roadshows in Bury, Croydon, Liverpool, and Preston, and where we were met with high demand for information.

The hours of Orchid’s freephone National Male Cancer Helpline were increased in March 2020 and demand was such that this continued throughout 2020-2021. Both the number and duration of calls increased in comparison with the previous year. Most of the sessions of the peer support groups which Orchid helps facilitate were delivered online, although there was some demand (when COVID-19 restrictions permitted it) for meeting in person with social distancing in place. Orchid Nurse Rob Cornes continued to support the St Bartholomew's Testicular Cancer Support Group. In the reporting year he was also able to refer men affected by penile or testicular cancer to Orchid’s telephone counselling service.

Orchid understands that talking to a GP about potential cancer symptoms, especially with virtual appointments, can be daunting for some men. Therefore, we created a checklist to we created a checklist to help them start the conversation with their GP and to help them get the most out of their

appointment. Another new resource launched during the period was a PSHE Association accredited lesson plan to help schools educate their pupils about testicular health and testicular cancer.

September’s annual Male Cancer Awareness Week was once again delivered mainly digitally, and had a particular focus on penile cancer for the fi rst time. Two highlights of the Week were the launch of a new animated fi lm called My Penile Cancer Journey, and the release of a moving video on the Rock Choir’s social media channels featuring photographs of male loved ones. The Week led on to the fi rst International Penile Cancer Awareness Day and a global virtual conference on penile cancer which was developed in partnership with the Global Society of Rare Genitourinary Tumours and the Australian charity, Check Your Tackle.

Alongside Nurse-led services, Orchid continued to support world-class research with our biggest grant being made to fund the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells project. Our report on pages 28-30 shows that Orchid funded researchers had a productive year despite the impact of COVID-19.

12 Orchid Cancer Appeal

The year in 1,200 numbers Downloads of the PSHE Association accredited lesson plan What is testicular cancer?

64,500 Pieces of Orchid’s specialist information disseminated

350 New followers on social media

19%

increase in the number of Helpline calls answered by Orchid’s Nurse Specialists compared to the previous year

10

Regional representatives recruited to the Task Force to support and help develop Orchid’s new project Overcoming the Barriers to Engaging with Prostate Cancer

108,000 Reach of the animated fi lm, My Penile Cancer Journey, launched on social media during Orchid’s Male Cancer Awareness Week

1,609,920 Number of social media accounts reached with male cancer messaging 217,000 Page views on Orchid’s website, an increase of 4% on previous year

50% Increase in the average length of Helpline calls compared to the previous year Number of people provided with 854 from a quali fi ed Nurse

Number of people provided with in-depth support and information from a quali fi ed Nurse

14 Orchid Cancer Appeal

Orchid’s work to save the lives of men from prostate, testicular and penile cancer during this reporting period was only possible because of the generosity of our wonderful supporters. Each and every contribution from individuals, community groups, Trusts and Foundations and companies helped us to make a difference, and we value all the support we received throughout what was another challenging year.

Fundraising

2019-2020 had seen a signi fi cant drop in income because of the impact of COVID-19. Whilst competition for funds remained high in 2020-2021 and the external environment was still uncertain, building relationships with existing and potential supporters continued to be a priority and Orchid’s income stabilised and began to regrow. The year ended with a 32% increase in income on the previous year, and Orchid would like to thank everyone who helped us in any way.

Orchid was delighted to receive the support of The National Lottery Community Fund via the noti fi cation and then fi rst payments of a 3-year grant to deliver a new prostate cancer programme across ten areas of England, alongside both restricted and unrestricted grants from Charitable Trusts and Foundations. Gifts from supporters were given in memory of loved ones and because of having been touched by male cancer. As COVID-19 restrictions lifted, our fundraising team

were pleased to be able to cheer and encourage supporters at events such as the London Landmarks Half Marathon in April, as well as supporting the many fundraising activities which individuals were organising across the UK. Signi fi cant support was received to fund male cancer research, and payroll giving continued to be a growing and valuable source of unrestricted income. Corporate support remained constant despite the challenges facing some of our supporters.

After the negative effect of the pandemic, our fundraising team and Trustees carried out a review of our activities to better understand the effect of COVID-19 on the different income streams. We used the learning from the previous year to help identify our fundraising strengths and new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises

Annual report and fi nancial statements 2020-2021 15

Focus on Ian Wisdom

Ian Wisdom is one of Orchid’s most committed supporters. For many years he has led his team comprising family and friends with great dedication to raise funds to help us fi ght male cancer. Ian is also passionate about raising awareness, to help people know who is at most risk and what to look out for. Thanks to Ian and his team, over £70,000 has been raised for Orchid, and thousands of people have gained important knowledge about male cancers.

the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of Trustees.

The highlight of his fundraising year is the annual Twyford Beer Festival. After the disappointment of the cancellation of the 2020 event because of COVID-19, Ian and his team worked tirelessly and with great resilience to make the 11th Twyford Beer Festival in June 2021 a safe and successful event. Everyone working or performing at the festival gave their time for free so that they could raise as much as possible to help Orchid, and this year saw their previous fundraising record broken.

The 2021 Twyford Beer Festival raised the most incredible sum of £12,000 to help Orchid fi ght male cancer. Not only that, but two Male Cancer Information Nurses attended the event to help Ian’s team raise awareness and to answer questions about prostate, testicular and penile cancer.

Orchid would like to thank Ian and all his team for their most wonderful dedication and support which is much valued, and which has been a signi fi cant contribution to Orchid’s work to save men’s lives from male cancer and to support those living with a diagnosis.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we did not receive any complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

16 OtthidtsntèrAp￿al

‘Having spoken with you on the Orchid Male Cancer Helpline

Prostate cancer 20

Testicular cancer 22

Penile cancer 24

Research 28

----- Start of picture text -----
Annual report and fi nancial statements 2020-2021 19
----- End of picture text -----

20 Orchid Cancer Appeal

Our impact: Prostate cancer

Over 52,000 men will be diagnosed with prostate cancer in the UK annually. Sadly, there are 11, 855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, 1 in 6 UK males will be diagnosed with prostate cancer in their lifetime.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those men who may be at risk of disease progression and those with mild or inactive disease. One of the interesting directions that this may take are so called liquid biopsies – the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

Orchid has a successful track record of working with the Black African and Black Caribbean community to raise awareness of Black men’s increased incidence of prostate cancer, supported by the creation of relevant

resources. Building on that experience and reaching out to people from a wider range of identi fi ed communities, May 2021 saw the start of a new threeyear project funded by The National Lottery Community Fund entitled Overcoming the Barriers to Engaging with Prostate Cancer. Through the project Orchid will recruit and train Volunteer Community Champions to help cascade prostate cancer messages to those at risk in Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham, and Wolverhampton.

The project team has been recruited, and the initial months of the project were spent on development work, including the recruitment of a Task Force comprising of ten key community in fl uencers who are helping to develop, implement and monitor key outputs and outcomes of the project. By the end of the reporting period resources such as the tool-kit (which will inform, guide and support the Volunteer Community Champions), policies, an evaluation framework and monitoring tools had been developed, and the recruitment of Volunteer Community Champions had begun.

Annual report and fi nancial statements 2020-2021 21

Making the vital leap and reaching out to Orchid: Leford’s story

When diagnosed with prostate cancer over 12 years ago at the age of 60, Leford was not displaying any of the classic symptoms of the disease but a friend urged him to get tested. Initial blood tests showed that his PSA levels were marginally high, but it was only a year later when he had further investigations that prostate cancer was diagnosed.

couple of years ago that he decided he needed to make the vital leap and contact Orchid who suggested he joined one of their prostate cancer support groups. He was part of both virtual and face-to-face groups and gained so much from them including the companionship with men who were experiencing similar emotions and had the same questions as he did.

Despite being heartbroken by his diagnosis, Leford did not want to worry anyone else, particularly not his wife who is a retired Nurse. He told people that his regular trips to the hospital related to other health issues he had, his diabetes and high blood pressure, and Leford really thought he could deal with his cancer alone. He later realised that he had been wrong to think he could.

Leford underwent surgery to remove his prostate, which was followed by radiotherapy and then three-monthly hormone treatments. It was a

Lockdown increased the isolation he felt at many times after his diagnosis, but the friends he made at the support group became his lifeline. He was also reassured by the knowledge that he could pick up the phone and speak to an Orchid Nurse, referring to them as his “Guardian Angels.”

Leford shared his story with Orchid, and permission to use it to raise awareness to help others, in the knowledge that his condition was terminal. As a Black man he was at increased risk of prostate cancer, something he had not initially been aware of. Sadly, Leford passed away in late 2021.

22 Orchid Cancer Appeal

Our impact: Testicular cancer

Testicular cancer is rare with around 2,300 men being diagnosed each year in the UK. Sadly around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of men diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many will only realise the full implication of their cancer journey when treatment ends and may

not be able to access either peer support or psychological support.

Demand for information about testicular cancer has been high over the year, and there was a 16% increase of sessions on Orchid’s testicular cancer microsite Your Privates compared to sessions in the previous year.

Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew’s Hospital in London, both physically and virtually.

In addition, Orchid’s telephone counselling service allows men affected by testicular cancer to access psychological support without the necessity of waiting for extended periods of time.

Orchid has also been working with the Thera Group, an organisation supporting people with learning disabilities, along with the breast cancer charity Coppafeel. The aim is to produce an informative awareness lea fl et on breast and testicular cancer with a target launch date of summer of 2022.

Annual report and fi nancial statements 2020-2021 23

Finding comfort in knowing what the future might hold: Jack’s story

When Jack was diagnosed with testicular cancer in 2018 he was 55 years old and had always thought this cancer only affected younger men. Indeed, testicular cancer is more common cancer in young men, and incidence rates for testicular cancer in the UK are highest in males aged 30 to 34, but older men can be affected too, as Jack discovered.

Jack had not thought he had anything to worry about, so was in complete shock when given a testicular cancer diagnosis. He found it a huge challenge to adjust to the diagnosis.

Following surgery, blood tests, x-ray and a CT scan, his cancer cells had metastasised to his abdominal lymph nodes. He had a cycle of chemotherapy to destroy the remaining cancer cells, and fortunately, after one cycle, he was told

that the treatment had been successful.

Jack knew he needed support to help him come to terms with his diagnosis and what it might mean for the future. He contacted Orchid’s con fi dential Male Cancer Helpline, and later contacted Orchid in person. He was comforted by the support he received, but it also gave Jack an insight into what he could expect in the future – such as how it would affect both his physical and mental health.

Jack feels he can now be positive about the future. He knows that he can always talk to a Specialist Nurse on Orchid’s Helpline, and that despite the potential challenges and issues he may face, he knows that there is support available from Orchid.

24 Orchid Cancer Appeal

Our impact: Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Sadly around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of all the male-speci fi c cancers penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function. Due to its intimate nature up to 50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics. Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support. In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral.

In response to the lack of awareness of this rare cancer, Male Cancer Awareness Week in September 2021 had a particular focus on penile cancer for the fi rst time ever. Orchid also created the fi rst International Penile Cancer Awareness Day (September 20th) and held a virtual conference for health care professionals and survivors.

In September 2021 Orchid facilitated and hosted a meeting of like-minded individuals, penile cancer survivors and those working within the fi eld of penile cancer, in London. The result of this was the formation of The Orchid Penile Cancer Steering Group. The aim of this group is to foster links with anyone throughout the world who actively provides psychological, medical and peer support in order to create a global resource and support network. The manifesto for this group, entitled The Way Forward, is currently being created by Orchid with the aim of disseminating its existence globally throughout 2022.

Support for those affected is needed, and Orchid continues to run its telephone counselling service to support men going through a diagnosis of penile cancer as well as providing online peer support opportunities.

With the support of two penile cancer patient advocates, Orchid have continued to work with eUrogen/Eurodis (The European Network for Rare Urogenital Diseases), a network of European urologists and institutions whose aim is to improve the treatment of rare urological diseases including penile cancer in Europe. Orchid have helped produce a patient journey document which will be adopted by the European network and used to illustrate the needs of penile cancer patients.

Annual report and fi nancial statements 2020-2021 25

One of the most signi fi cant conversations of his life: Ted’s story

Like so many men, when Ted was diagnosed with penile cancer fi ve years ago at the age of 58, he had never heard of this rare cancer.

His medical treatment for the disease made him feel anxious and confused, and he was completely surprised by the psychological impact of his diagnosis. He didn’t know anyone else who had been affected by penile cancer and felt he needed to know if what he was experiencing was what also happened to other men.

Ted called Orchid’s Freephone Male Cancer Helpline and his call was answered by Rob Cornes, Orchid’s lead Male Cancer Information Nurse Specialist. Rob empathised with his situation, provided really important practical advice, and importantly, Rob completely understood how he was feeling. Ted later described his rst call to Orchid as “one of

the most crucial and signi fi cant conversations I have ever had.”

The Helpline is just one of the ways in which Orchid is able to help those affected by penile cancer. As well as dealing with the immediate issues, Rob suggested that Ted join an online support group which he facilitates. This provided Ted with the opportunity to meet others affected by penile cancer, and he was able to share his experience and gain mutual support from others in the group.

Rob also offered Ted the opportunity to be referred to Orchid’s telephone counselling service for men diagnosed either with penile cancer or testicular cancer which he accepted. “The counselling service has proved invaluable in allowing me to address long standing issues which I hadn’t realised remained unresolved."

‘I hadn’t realised that trans women and non-binary people can also be at risk of

Annual report and fi nancial statements 2020-2021 27

28 Orchid Cancer Appeal

Orchid’s research programme is an investment in the well-being of current and future generations. If we understand the three male-speci fi c cancers, how they work and how to treat them, we can offer a better and brighter outlook for our loved ones, their children and grandchildren.

Our impact: research

In September 2021 the Orchid Research Tissue Bank was renamed in recognition of the most wonderful contribution made to Orchid by our former Chair, Robert Lane CBE, who died unexpectedly in February 2020.

Despite the impact of COVID-19, 2020-2021 was another productive year for the researchers in the Robert Lane Tissue Bank. There was a signi fi cant build-up of research capacity, important research fi ndings and numerous publications in leading international journals.

The Tissue Bank has now collected over 13,000 specimens in total, representing an internationally signi fi cant resource for past and future research into all three male-speci fi c cancers. Rather than collecting all tumours, this is a ‘bespoke’ bank often with long term clinical follow up and connected to clinical trial data, making it an invaluable resource for the future. Speci fi cally, it holds:

• Tumours from nine separate clinical trials.

• Over 600 penile cancer specimens.

• Over 3,000 testicular cancer specimens.

• Over 6,000 prostate cancer specimens.

• Over 1,200 blood samples collected and separated into Circulating Tumour Cells (CTCs), plasma, red blood cells, white blood cells and platelets for separate storage and future research.

While the development of new drugs and therapies prolongs patients’ survival period, advanced cancers are still rarely cured, yet cancers diagnosed at early stage are mostly curable by a number of treatments. However, detection of cancer at an early stage is still

challenging for many cancer types, including prostate cancer. Currently, cancer diagnosis is based on tissue biopsy. In their previous work, the researchers investigated a blood test in prostate cancer detection using a platform, Parsortix made by ANGLE plc, to ef fi ciently detect cancer cells spread into the blood circulation (CTCs). This showed that the detection of cancer cells in the blood predict the prostate cancer tissue biopsy outcome with high accuracy, which not only distinguishes cancer from benign, but also indolent from aggressive cancers. In the aim to change the paradigm of prostate cancer diagnosis and also guide the treatment of cancer patients by monitoring cancer aggressiveness and progression by a blood test, they have started the validation study locally (Barts Hospital) and have set up the national network for a multiple centre validation study including QMUL (Barts and Whipps Cross Hospitals), University College of London (UCL)(UCL Hospitals), Imperial College (Hammersmith and Charing Cross Hospitals), University of Cambridge (Addenbrooke Hospital) and University of Newcastle (Newcastle upon Tyne Hospitals NHS Foundation Trust), a critical step to move this prostate cancer blood test into clinical use.

The CTC detection method used previously is timeconsuming. In collaboration with ANGLE plc, researchers investigated faster CTC isolation methods and evaluated their ef fi ciency in CTC detection in comparison with the previously established method. In collaboration with ANGLE plc, they have also established a method of using a method called, HyZip, which can simultaneously analyse a large number of CTC RNAs (ribonucleic acid) to further increase the

Annual report and fi nancial statements 2020-2021 29

accuracy of detecting clinically signi fi cant prostate cancer. All these will facilitate the planned multiplecentre clinical study and the clinical implementation of detecting CTCs for prostate cancer diagnosis.

In collaboration with researchers at Paci fi c Northwest National Laboratories in USA, the team has also developed a proteomics technology (analysis of thousands of proteins simultaneously), applicable for CTC analysis.

CTCs clustered together are able to survive the immune cell attack in the blood circulation better than isolated single CTCs, therefore, they may form cancer metastasis easier than single CTCs. The team found that CTC clusters were found signi fi cantly more and larger (more CTCs per cluster) in patients with metastasis than non-metastatic prostate cancer. In non- non-metastatic cancer patients, more CTC clusters were found in aggressive than latent cases.

The researchers have also started to investigate the potential of using other materials/products that cancer cells released into the blood circulation. They have detected in peripheral blood certain prostate cancer cell released molecules, which are used by cancer cells to communicate with other body cells for cancer growth and metastasis, and their appearance is associated with the development of hormone therapy resistance of prostate cancer. The work has been published in Frontiers in Cell and Developmental Biology. The team has now identi fi ed by the advanced genetic sequencing technology that these molecules differentially presented in blood samples between prostate cancer and non-cancer patients.

Not all prostate cancers diagnosed at early stage are life threatening, so while the aim is to treat aggressive prostate cancer ef fi ciently to cure the cancer, reducing side effects of treatment such as impotence and incontinence by avoiding unnecessary therapies for non-signi fi cant prostate cancer is equally important. Currently, cancer pathology grade, clinical stage and blood PSA (prostate-speci fi c antigen) level have been used to decide who requires treatment and who can be safely ‘observed’ with routine follow up. Further molecular biomarkers are required to improve the treatment strati fi cation, which is the team’s long-term research focus. The team continued the study with the Trans-Atlantic Cohort, now with over 3,000 cases, and have validated that the biomarkers they identi fi ed are able to determine the aggressiveness of prostate cancer). Following their previous fi ndings of using the protein Ki67 as aggressive cancer biomarker at prostate cancer diagnosis, the team further analysed Ki67 in advancing/metastatic prostate cancer samples from the largest prostate cancer national clinical study investigating drug treatment ef fi cacy. They found that Ki67 may be a powerful prognostic and even predictive marker in advanced prostate cancer, helping to determine treatment.

Following the previous success in applying arti fi cial intelligence, the team published the fi nding that intelligence assistance signi fi cantly improves Gleason grading of prostate biopsies by pathologists in Modern Pathology. As an international leading pathologist in urological cancers, Professor Berney published four more papers in the past year about improving the pathological diagnosis of prostate cancer.

30 Orchid Cancer Appeal

Prevention is a more ef fi cient approach than therapies to reduce death from cancer. The team have been involved in a prostate cancer prevention clinical study (PROVENT phase 1), aiming to use aspirin and vitamin D to prevent indolent cancer from progressing into aggressive cancer. The pilot study has recently been successfully completed. Patient samples are stored in the Robert Lane Tissue Bank under a Human Tissue Authority license awaiting further ethical approval for use in future research.

The genetic changes in cancer cells determines cancer development, behaviour and the treatment responses. Therefore, the team have continued the collaborative work with the international consortiums in prostate cancer genetic risk and somatic genetic abnormality studies, which led to high pro fi le publications in the top scienti fi c journals, Nature Genetics and Nature Communications. These fi ndings are landmarks for our understanding of human cancer genetic alterations and will promote the development of new approaches in cancer diagnosis and treatment.

administered to those men who need it, and sparing the toxic side effects for those who do not. It is hoped these papers will become a mainstay of pathological information to guide treatment for both localised and advanced germ cell tumours. As well as publications, fi rst prize was awarded at the National Germ Cell Group (NGCG) for a poster for review of pathology and outcome on Primary Somatic Transformation of Testicular Germ Cell Tumours.

The Tissue Bank team continued to collect penile cancer samples from St George’s Hospital for future utilisation.

For testicular cancer, there have been publications in relation to using tumour node metastasis staging system as predictors for non-seminomatous germ cell tumours and management of patients at late stage after chemotherapy as well as a study carried out in UK with 216 patients for the ef fi cacy of the use of a drug in metastatic seminoma. In addition, an overview of the impact on treatment decision making on testicular cancer has been done by the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). These studies all have the aim of appropriate and re fi ned targeting of chemotherapy: to make sure it is

Annual report and fi nancial statements 2020-2021 31

As a teacher I am so glad to have proper testicular cancer resources from Orchid and accredited by the PSHE Association as they tackle a potentially dif fi cult subject in an engaging way

32 Orchid Cancer Appeal

The reporting year ended with the successful delivery of Orchid’s thirteenth Male Cancer Awareness Week which highlighted all three male-speci fi c cancers, with a particular focus on the rare penile cancer.

The year ahead

Raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new fi nancial year. To ensure this is supported by the best possible resources and information, Orchid Nurse Rob Cornes has committed to undertake a review of Orchid’s information with view to attaining the PIF TICK which is the UK-wide Quality Mark for Health Information. Alongside that, three new resources are planned, including a z card about all three male cancers which will be used at Roadshows in particular, a fi lm about advanced prostate cancer, and a series of posters.

In September 2021 we had returned to delivering Male Cancer Information Roadshows in the heart of local communities, and whilst we will monitor the external environment, we plan to run these throughout the coming year as funding becomes available. Roadshow locations have been identi fi ed for the fi rst three months of the year and delivery planned. Orchid’s Health at Work programme will be grown, and initial bookings for the year suggest there is a real appetite for Orchid’s Male Cancer Information Nurse Specialists to talk to workforces, both virtually and in person. Orchid has been working with Tesco to help colleagues learn about male cancer, and staff will be delivering tailored Roadshows for Tesco in the year ahead.

Our plan is to further increase the reach of our social media activity and population type approaches. Case studies are being gathered as there is evidence to show that sharing the stories of people affected by male cancer is an effective way to raise awareness and to highlight the ways Orchid’s Nurse-led services

can help. These case studies will also be used to support our fundraising activities.

In 2020-2021 the staff team had been recruited and work begun on our new project called Overcoming the Barriers to Engaging with Prostate Cancer, funded by The National Lottery Community Fund. The year ahead will see the recruitment and training of a large team of Volunteer Community Champions who will cascade prostate cancer health messages to targeted groups in the ten identi fi ed areas in which the project is being delivered.

Orchid’s Male Cancer Awareness Week will take place between 12-18 September 2022 and have a particular focus on older men and testicular cancer. Testicular cancer tends to affect a younger age group than most other cancers, but Orchid has identi fi ed a need to highlight the fact that older men can be affected too, and to develop support aimed speci fi cally at this older age group. The second International Penile Cancer Awareness Day will take place on 20 September.

Supporting those affected or concerned is a high priority for the coming year. The Freephone National Male Cancer Helpline will continue to operate with its increased hours, and if funding can be secured, the hours will be increased further to reduce the number of calls missed. We remain committed to offering peer support opportunities, and those currently delivered through the Penile Cancer Support Service in Scotland will be brought into our core services. We will continue to offer a telephone counselling service to those affected by penile or testicular cancer. Regarding penile cancer, Orchid has created a steering group, made up of survivors and healthcare

Annual report and fi nancial statements 2020-2021 33

professionals, who are developing a programme of ongoing initiatives, called The Way Forward. Through this, Orchid will work on a global level to improve the patient journey for those with penile cancer.

Orchid’s roots are in male cancer research, and we will continue to invest in world-class innovative male cancer research to bene fi t the well-being of current and future generations of men. Going into the year, Trustees identi ed two areas funds would be directed towards.

One is The Robert Lane Tissue Bank incorporating the Circulating Tumour Cell project, which is led by Professors Dan Berney and Yong-Jie Lu. Collection and validation of tissue from male cancers from high quality clinical trials and cohorts will advance our understanding of male cancers, creating better prognostic and predictive targets for treatment and diagnosis. Furthermore, the project will also increase understanding of the molecular mechanisms of prostate cancer development, progression and response to therapies and develop biomarkers for the diagnosis, prognosis and treatment response prediction of prostate cancer as well as testicular and penile cancers. The other male cancer research area Orchid will be focussing on is to award a signi fi cant grant from funds secured for the Orchid Research Innovation Fund.

Securing adequate funding at the best possible return on investment is paramount to delivering our ambitious plans for the year ahead. Having reviewed all fundraising activities and seen our income stabilised, our fundraising strategy for 2021-2022 focusses on continuing to grow revenue across all income streams.

The fi rst day of the year ahead saw our wonderful team of runners fundraising in the London Marathon, and the charity is receiving interest in events throughout the year now that external events are being planned after so many were postponed because of COVID-19. We are excited that Orchid will be the recipient of a Radio 4 Appeal in April 2022, and September 2022 will see the return of the successful fundraising event, Orchid’s Willy Waddle. Digital fundraising is a new area for the charity, and a Christmas appeal will be launched on Facebook. To make giving easier for our supporters, we will be looking at a new fundraising platform.

We will also continue to explore other new income generating opportunities, and to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, The National Lottery Community Fund and the individuals and community groups who support us with donations and fundraise on our behalf.

Having reviewed training need, we will invest in training for our small staff team, with the fi rst priorities being Equality, Diversity, Equity and Inclusion, and the use of our fundraising database. Orchid also recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Orchid’s work would not be possible without the generosity of our supporters, and the charity is grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the coming year.

Orchid CancèrApp . ¥

‘Contacting the helpine was the most important call of my life. For the rst time

36 Orchid Cancer Appeal

Governance

Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding integrated scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our in fl uence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Annual report and fi nancial statements 2020-2021 37

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair’s aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from of fi ce in rotation, in order of longevity of appointment and are eligible to be reappointed. Throughout the COVID-19 pandemic Trustees met virtually.

Trustee training and induction

On appointment, Trustees receive a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

• At the strategic level, the Board of Trustees regularly reviews Orchid’s direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.

• The Finance Committee is responsible for the fi nancial oversight of the Charity including budgeting, fi nancial planning and monitoring as well as fi nancial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2021, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

• To improve ef fi ciency, Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.

• At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept appraised of personnel, awareness, research programme and budgetary issues.

38 Orchid Cancer Appeal

Public bene t

The Trustees con fi rm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public bene fi t including (PB2 Public Bene fi t: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation’s strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for speci fi c tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the veri fi cation of outcomes, a Scienti fi c Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and ef fi ciency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identi fi es risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identi fi es risks under the following headings:

Governance and compliance Operational Financial

Environmental/external Research Quality assurance

Each identi fi ed risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identi fi ed and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Speci fi c risks which, if materialised, would have had a signi fi cant impact on the Charity have been identi fi ed. These are shown in the table on the next page.

Annual report and fi nancial statements 2020-2021 39

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to.

Mitigation

• An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and fi nancial, are covered by suitably quali fi ed professionals

• Training and support for Board of Trustees and Finance Committee

• Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

• Annual salary review to include benchmarking of compensation and bene ts

• Staff development, training and succession planning programmes

• Communication programme to ensure staff are involved in the development of and progress towards Orchid’s strategy and annual workplan

Financial

Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a signi fi cant fall in income

Mitigation

• Annual budgeting and ongoing management, reporting and monitoring of fi nancial performance

• Diversi cation of income streams

• Ongoing consideration of market and consumer trends and regulations including GDPR

• Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

Mitigation

• Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed

• Chief Executive and Nurse Specialists attend key events and forums to help shape agenda

• Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid’s strategy

Research

Orchid’s Research Programme fails to deliver results

Mitigation

• Scrutiny and approval of research funding applications by an expert Scienti fi c Advisory Board

• Annual review of progress

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

• Services developed, delivered and evaluated in line with agreed protocol and standards

• Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)

• All information materials and content regularly reviewed and updated

• High-quality training for staff

40 Orchid Cancer Appeal

Financial review

Results for the year

Income for the year ended 30 September 2021 totalled £530,278 (2020: £401,181). After total expenditure of £673,004 (2020: £756,577), the year's activities show a net de fi cit of £142,726 (2020: de fi cit of £355,396). Total reserves at the end of the year amounted to £440,280 (2020: £583,006).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen dif fi culty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

• risks associated with each income and expenditure stream differing from that budgeted

• planned activity level

• organisational commitments.

The available free reserves net of tangible fi xed assets are £150,886 (2020: £139,396). It is the Charity’s policy

to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £145,000-£192,000.

Formal statements

Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the fi nancial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare fi nancial statements for each fi nancial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these fi nancial statements, the Trustees are required to:

• select suitable accounting policies and then apply them consistently;

• observe the methods and principles in the Charities SORP;

• make judgements and estimates that are reasonable and prudent;

• state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the fi nancial statements;

Annual report and fi nancial statements 2020-2021 41

• prepare the fi nancial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the fi nancial position of the charitable company and enable them to ensure that the fi nancial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and fi nancial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of fi nancial statements may differ from legislation in other jurisdictions.

So far as each of the directors at the time the Trustees’ report is approved is aware:

a) there is no relevant information of which the examiner is unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in of fi ce and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The fi nancial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees

C S Osborne Chairman of Trustees 14/06/2022

42 Orchid Cancer Appeal

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2021.

Responsibilities and basis of report

As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satis fi ed myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

1. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

James Saunders FCCA DChA 16/06/2022

For and on behalf of

Moore Kingston Smith LLP Chartered Accountants 6th Floor, 9 Appold Street, London EC2A 2AP

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I con fi rm that I am quali fi ed to undertake the examination because I am a member of the Association of Chartered Certi fi ed Accountants, which is one of the listed bodies.

I have completed my examination. I con fi rm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or

2. the accounts do not accord with those records; or

3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair view which is not a matter considered as part of an independent examination; or

Annual report and fi nancial statements 2020-2021 43

Statement of nancial activities

(incorporating an income and expenditure account) For the year ended 30 September 2021

Year ended Year ended Unrestricted Restricted 30 September 30 September Note Total Total 2021 2020 £ £ £ £ Income from: Donations and Legacies 2 250,530 190,050 440,580 350,828 Charitable Activities 4 - 89,497 89,497 47,571 Trading Activities 177 - 177 534 Investment income 24 - 24 2,248 Total income 250,731 279,547 530,278 401,181 Expenditure on: Raising funds Fundraising (donations and grants) 5 185,083 - 185,083 187,210 Charitable Activities Education and Awareness 5 74,173 233,210 307,383 426,471 Research 5 106,638 73,900 180,538 142,896 Total expenditure 365,894 307,110 673,004 756,577 Net income / (expenditure) and net movement in funds 5,6 (115,163) (27,563) (142,726) (355,396) Reconciliation of funds Total funds brought forward 394,129 188,877 583,006 938,402 Total funds carried forward 278,966 161,314 440,280 583,006

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the nancial statements.

44 Orchid Cancer Appeal

Balance sheet

As at 30 September 2021

30 September 30 September 2021 2020 Note £ £ £ £ Fixed Assets Tangible Assets 10 2,971 366 Current Assets Cash at bank and in hand 508,854 727,441 Debtors 11 77,325 136,586 586,179 864,027 CREDITORS Amounts due within one year 12 (148,870) (281,387) Net Current Assets 437,309 582,640 Total Assets less Current Liabilities 13 440,280 583,006 NET ASSETS 440,280 583,006 Represented by: 14 General Unrestricted Funds 157,158 135,382 Designated Funds 121,808 258,747 278,966 394,129 Restricted funds 161,314 188,877 440,280 583,006

The company is limited by guarantee.

The fi nancial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Mr C S Osborne

Company number 3963360

Annual report and fi nancial statements 2020-2021 45

Statement of cash ows

For the year ended 30 September 2021

2021 2020 £ £ £ £ Cash fl ows from operating activities: Net expenditure for the year (142,726) (355,396) Adjustments for: Depreciation charges 1,486 729 Interest (24) (2,248) Decrease in debtors 59,261 50,460 (Decrease) in creditors (132,517) (25,980) Net cash provided by operating activities (214,520) (332,435) Cash fl ows from investing activities: Interest 24 2,248 Disposal of fi xed assets - (1,091) Purchase of fi xed asset (4,091) - Disposals of investments - 912,297 Net cash used in investing activities (4,067) 913,454 Change in cash and cash equivalents in the year (218,587) 581,019 Cash and cash equivalents at the beginning of the year 727,441 146,422 Cash and cash equivalents at the end of the year 508,854 727,441 Analysis of cash and cash equivalents Cash at bank and in hand 508,854 727,441 508,854 727,441

46 Orchid Cancer Appeal

Notes to the nancial statements

1. Accounting policies

Basis of Preparation

These fi nancial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public bene fi t entity for the purposes of FRS 102 and therefore has also prepared the fi nancial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these fi nancial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these fi nancial statements and have considered the impact of the coronavirus pandemic on the charity’s operations. In particular the trustees have considered the charity’s forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2021/22; however, there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The charity has secured a 3-year project funded by The National Lottery Community Fund: Overcoming the Barriers to Engaging with Prostate Cancer. The aim is to work in targeted locations across England and focus on supporting individuals from identi fi ed communities to overcoming barriers to engaging with prostate cancer. This will enable Orchid to continue its valued work. Many fundraising events have been postponed from 2020 and as a result Orchid has an all-time number of runners signed up for events in the Summer of 2021. Whilst there is still some risk around fundraising events being held in the Summer, Orchid is hopeful that the relaxation of Covid-19 restrictions will enable these events to take place. The National Lottery project along with continued support from loyal donors and will enable Orchid to continue to as a going concern.

The trustees con fi rm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its fi nancial statements.

Functional currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The fi nancial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised. Computer and Of fi ce Equipment - 33 1/3% on written down value.

Funds accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for speci fi c purposes.

Restricted funds are funds subject to speci fi c restrictions imposed by donors or by the nature of the appeal. The purpose and use of the Charity’s restricted funds is set out in the notes to the nancial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/ distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quanti fi able. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Annual report and fi nancial statements 2020-2021 47

Expenditure

Cost of raising funds includes costs associated with the fundraising events in furtherance of the Charity’s objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity’s objects.

Governance costs are those incurred in connection with the management of the Charity’s assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are ful fi lled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial instruments

The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its fi nancial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the fi nancial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic nancial instruments under FRS 102.

Debtors

Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash fl ows, cash and cash equivalents consist of cash and cash equivalents as de fi ned above.

Creditors

Short term trade creditors are measured at the transaction price. Other fi nancial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension scheme

The Charity operates a de fi ned contribution stakeholder pension scheme. The amount charged to the statement of fi nancial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee bene fi ts

The cost of short-term employee bene fi ts are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee’s services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have signi fi cant effect on the amounts recognised in the fi nancial statements nor do any estimates or assumptions carry a signi fi cant risk of material adjustment in the next fi nancial year.

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

48 Orchid Cancer Appeal

Notes to the nancial statements

2. Donations

Current year Year ended Year ended 30 September 30 September 2021 2020 Restricted Unrestricted Total Total £ £ £ £ Individuals 92,800 51,044 143,844 85,501 Legacies - - - 17,000 Corporates - 35,771 35,771 22,434 Trusts and Foundations 97,250 17,050 114,300 99,365 Fundraising Events - 146,665 146,665 114,545 Total 190,050 250,530 440,580 338,845 Prior year Year ended 30 September 2020 Restricted Unrestricted Total £ £ £ Individuals 16,200 69,301 85,501 Legacies - 17,000 17,000 Corporates 5,000 17,434 22,434 Trusts and Foundations 88,115 11,250 99,365 Fundraising Events - 114,545 114,545 Total 109,315 229,530 338,845

Annual report and fi nancial statements 2020-2021 49

Notes to the nancial statements

3. Fundraising events

Current year Year ended Year ended 30 September 30 September 2021 2020 Restricted Unrestricted Total Total £ £ £ £ Cycling events - 11,257 11,257 3,249 Running events - 56,100 56,100 39,017 Third party organised events - 76,943 76,943 64,346 Other - 2,365 2,365 7,933 Total - 146,665 146,665 114,545 Prior year Year ended 30 September 2020 Restricted Unrestricted Total £ £ £ Cycling events - 3,249 3,249 Running events - 39,017 39,017 Third party organised events - 64,346 64,346 Other - 7,933 7,933 Total - 114,545 114,545

50 Orchid Cancer Appeal

Notes to the nancial statements

4. Charitable activities

Current year Year ended Year ended 30 September 30 September 2021 2020 Restricted Unrestricted Total Total £ £ £ £ Grants - National Lottery Community Fund Covid 19 Emergency Funding - - - 47,571 The National Lottery Community Fund - RC England-wide 89,497 - 89,497 - Total 89,497 - 89,497 47,571 Prior year Year ended 30 September 2020 Restricted Unrestricted Total £ £ £ Grants - National Lottery Community Fund Covid 19 Emergency Funding 47,571 - 47,571 Total 47,571 - 47,571

Annual report and fi nancial statements 2020-2021 51

Notes to the nancial statements

5. Total expenditure

Current year Year ended Year ended 30 September 30 September Cost of Education and 2021 2020 raising funds awareness Research Total Total £ £ £ £ £ Grants - - 154,896 154,896 112,876 Staff costs 88,500 133,468 17,044 239,012 339,143 Fundraising expenses 51,935 - - 51,935 26,277 Information materials - 66,371 - 66,371 72,185 Direct costs - 30,322 30,322 79,807 140,435 230,161 171,940 542,536 630,288 Support costs Depreciation 499 891 96 1,486 729 Other 33,057 59,054 6,366 98,477 105,333 Governance - staff costs 9,119 13,753 1,756 24,628 8,717 Governance - examiner’s fees 1,973 3,524 380 5,877 11,510 44,648 77,222 8,598 130,468 126,289 Total expenditure 185,083 307,383 180,538 673,004 756,578 Prior year 187,210 426,471 142,896 756,578

52 Orchid Cancer Appeal

Notes to the nancial statements

6. Grants awarded

Year ended Year ended 30 September 30 September 2021 2020 £ £ Grant commitments brought forward 205,415 199,002 Institutional grants for medical research awarded during year: Barts and London School of Medicine 138,896 112,876 Payments made during period/year (291,459) (106,463) Grant commitments carried forward 52,852 205,415 Payable less than one year 52,852 205,415 Payable two to fi ve years - -

Notes to the nancial statements

7. Net expenditure for the year

This is stated after charging: Year ended Year ended 30 September 30 September 2021 2020 £ £ Depreciation 1,486 729 Examiner’s remuneration: Examination 5,300 - Auditor’s remuneration: Audit - 9,592 Trustees’ remuneration - - Trustees’ expenses - -

Annual report and fi nancial statements 2020-2021 53

Notes to the nancial statements

8. Staff costs and numbers

Staff cost were as follows: Year ended Year ended 30 September 30 September 2021 2020 £ £ Salaries and wages 182,602 241,235 Social security costs 13,020 20,787 Pension contributions 1,364 2,442 196,986 264,464 Consultants’ costs 66,655 83,397 263,641 347,861

During the year ended 30 September 2021 one employee earned more than £60,000 (Year to 30 September 2020: one). The pension contribution paid in respect of this employee totalled £Nil (2020: £Nil)

The key management personnel of the Charity comprise the Trustees and the Chief Executive.

The charity trustees do not receive remuneration.

The total remuneration of the chief executive was £66,494 (year ended 30 September 2020: £80,177).

The average number of employees during the year was 6.7 (2020: 5.8)

The average number of employees during the year on a headcount basis was as follows:

2021 2020 No. No. Fundraising 2.1 1.7 Education and awareness 4.3 5.1 Grant support 0.3 0.2 6.7 7

54 Orchid Cancer Appeal

Notes to the nancial statements

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

Notes to the nancial statements

10. Tangible fi xed assets

Computer and 30 September 30 September of fi ce equipment 2021 2020 Total Total Total £ £ £ Cost At the start of the period 3,224 3,224 2,674 Additions 4,091 4,091 2,187 Disposals - - (1,637) At the end of the period 7,315 7,315 3,224 Depreciation At the start of the period 2,858 2,858 2,674 Charge for the period 1,486 1,486 729 - Disposals - (545) At the end of the period 4,344 4,344 2,858 Net book value At the end of the period 2,971 2,971 366 At the start of the period 366 366 -

Annual report and fi nancial statements 2020-2021 55

Notes to the nancial statements

11. Debtors

Year ended Year ended 30 September 30 September 2021 2020 £ £ Prepayments 45,594 83,777 Other debtors and accrued income 31,731 52,809 77,325 136,586

Notes to the nancial statements

12. Creditors: amounts due within one year

Year ended Year ended 30 September 30 September 2021 2020 £ £ Grants payable 87,576 205,415 Trade and other creditors 20,799 34,691 Taxation and Social Security - 5,530 Accruals 40,495 35,754 148,870 281,390

56 Orchid Cancer Appeal

Notes to the nancial statements

13. Movements in funds

Current year Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 135,382 250,731 (228,955) 157,158 - Designated – Research 53,281 - (53,281) Designated – Development 121,808 - - 121,808 - Designated – Awareness 83,658 - (83,658) Total unrestricted 394,129 250,731 (365,894) 278,966 Restricted - Testicular Cancer Counselling - 3,000 (3,000) The National Lottery Community Fund - RC England-wide - 89,497 (57,052) 32,445 Male Cancer Nurse Information Specialist - other funders 56,974 6,000 (54,722) 8,252 The Innovation Research Project 16,200 92,800 (16,200) 92,800 - Penile Cancer Peer Support 5,000 2,500 (7,500) Education and Awareness 11,250 23,050 (29,300) 5,000 Student Study and Travel Scholarships 6,729 - - 6,729 Roadshows 37,527 1,000 (35,667) 2,860 - Robert Lane Tissue Bank - 57,700 (57,700) Young Person’s Testicular Cancer Project 10,369 - (7,141) 3,228 - National Lottery Community Fund – Covid 19 Emergency 37,328 - (37,328) City of London Corporation 7,500 4,000 (1,500) 10,000 Total restricted 188,877 279,547 (307,110) 161,314 Total funds 583,006 530,278 (673,004) 440,280

Annual report and fi nancial statements 2020-2021 57

Notes to the nancial statements

13. Movements in funds (continued)

Prior year Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 334,804 244,295 (443,717) 135,382 Designated – Research 166,157 - (112,876) 53,281 Designated – Development 121,808 - - 121,808 Designated – Awareness 83,658 - - 83,658 Total unrestricted 706,427 244,295 (556,593) 394,129 Restricted Testicular Cancer Counselling 16,247 - (16,247) - Big Lottery Reaching Communities Fund 51,469 - (51,469) - Male Cancer Nurse Information Specialist - other funders 76,706 - (19,732) 56,974 The Innovation Research Project 0 16,200 - 16,200 Penile Cancer Peer Support 4,492 5,000 (4,492) 5,000 Education and Awareness - 33,250 (22,000) 11,250 Student Study and Travel Scholarships 6,729 - - 6,729 Roadshows 30,926 33,415 (26,814) 37,527 Tissue Bank - 13,750 (13,750) - Young Person’s Testicular Cancer Project 10,369 - - 10,369 National Lottery Community Fund – Covid 19 Emergency - 47,571 (10,243) 37,328 City of London Corporation - 7,500 - 7,500 Services - 200 (200) - North East London Cancer Network 35,037 - (35,037) - Total restricted 231,975 156,886 (199,984) 188,877 Total funds 938,402 401,181 (756,577) 583,006

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees’ discretion to be used to help fund speci fi c awareness activities.

58 Orchid Cancer Appeal

Notes to the nancial statements

14. Analysis of net assets between funds

Current year Total funds at Unrestricted Restricted 30 September funds funds 2021 £ £ £ Fixed assets 2,971 2,971 Current assets 424,865 161,314 586,179 Creditors due within one year (148,870) (148,870) Net assets at 30 September 2021 278,966 161,314 440,280 Prior year Total funds at Unrestricted Restricted 30 September funds funds 2020 £ £ £ Fixed assets 366 366 Current assets 613,437 250,590 864,027 Creditors due within one year (281,387) (281,387) Net assets at 30 September 2020 332,416 250,590 583,006

Notes to the nancial statements

15. Related party transactions

Aggregate donations of £80,000 were received from trustees in the year ended 30 September 2021. (Year to 30 September 2020: none)

Annual report and fi nancial statements 2020-2021 59

Notes to the nancial statements

16. Financial commitments

For the year ended 30 September 2021, the charity was committed to making the following future payments under non cancellable operating leases.

Year ended Year ended 30 September 30 September 2021 2020 £ £ Land and buildings - - Expiring within one year 14,184 14,184 14,184 14,184

ORCHID FIGHTING MALE CANCER